Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491276 | 0.89 | CYP4F2 (0.59) | CYP4F2CYP4A11LMNASMN1; SMN2DRD2 | |
| SCHEMBL8984891 | 0.88 | CYP4F2 (0.58) | CYP4F2CYP4A11LMNASMN1; SMN2FFAR1 | |
| SCHEMBL8912630 | 0.88 | CYP4F2 (0.58) | CYP4F2CYP4A11ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL491225 | 0.87 | CYP19A1 (0.60) | CYP4F2CYP4A11LMNASMN1; SMN2ALOX5 | |
| SCHEMBL2432179 | 0.87 | CYP4F2 (0.56) | CYP4F2CYP4A11LMNASMN1; SMN2CYP4Z1 | |
| SCHEMBL2432961 | 0.85 | CYP4F2 (0.55) | CYP4F2CYP4A11ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL22000638 | 0.85 | CYP4F2 (0.55) | CYP4F2CYP4A11ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4450867 | 0.85 | CYP4F2 (0.55) | CYP4F2CYP4A11ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5685284 | 0.85 | CALM1 (0.57) | CYP4F2CYP4A11ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL30594197 | 0.85 | CYP4F2 (0.55) | CYP4F2CYP4A11ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120093724-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-19 | — | — | US | disclosed |
| US-6235789-B1 | GLANDULAR DISORDERS; SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0781271-B1 | BENZOCYCLOALKENE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-06-07 | — | — | EP | disclosed |
| EP-0781271-A1 | BENZOCYCLOALKENE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008466-A1 | BENZOCYCLOALKENE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-21 | — | — | WO | disclosed |
| US-4612376-A | Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093724-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | KLK3, KLK2, KLK5 | CYP4F2 1712/4885CYP4A11 3497/4885HPGD 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.